CN101686726A - Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs - Google Patents

Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs Download PDF

Info

Publication number
CN101686726A
CN101686726A CN200880015561A CN200880015561A CN101686726A CN 101686726 A CN101686726 A CN 101686726A CN 200880015561 A CN200880015561 A CN 200880015561A CN 200880015561 A CN200880015561 A CN 200880015561A CN 101686726 A CN101686726 A CN 101686726A
Authority
CN
China
Prior art keywords
calcium
composition
application
weight
butterfat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880015561A
Other languages
Chinese (zh)
Inventor
京特·萨瓦特兹奇
马尔科·萧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUMANA GmbH
Original Assignee
HUMANA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUMANA GmbH filed Critical HUMANA GmbH
Priority to CN201610173158.8A priority Critical patent/CN105962374A/en
Publication of CN101686726A publication Critical patent/CN101686726A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/06—Mixtures of whey with milk products or milk components
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
    • A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a kind of be used for making improve calcium absorb use combination of agents thing, described composition comprise preferred with palmitic acid at the bit esterified at least a butterfat of sn-2 and comprise at least a lactoprotein alternatively and/or at least a milk protein hydrolyzates.

Description

Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs
Technical field
The present invention relates to butterfat-milk protein composition is used for improving the application that calcium absorbs at human body.
Background technology
Because calcium deficiency is the pathogenesis of some typical disease of modern society, therefore human body being supplied with calcium is one of current most important target.
In whole life process, all need an amount of calcium to supply with.If, then can take place earlier, and when older, osteoporosis can take place to the bone undersupply at the early stage calcium of health not being supplied with capacity of infant.The deficiency that calcium is supplied with will cause the reduction of bone density.Yet before osteoporosis took place, calcium deficiency can cause metabolic very big disorder.Symptom is that the irritability of N﹠M increases, and this may cause muscle cramp.
People know for a long time, and breast is one of most important source of supplying with for human body calcium.Because relatively large calcium is contained in the Ruzhong, therefore all recommend conventional nutriment such as breast or dairy products about all relevant nutrition suggestions of replenishing the calcium.Yet, so far, it is very undesirable that the fat in Ruzhong is considered to, and one of reason is because in from the index information that consumes interested every profession and trade for plant fat, and butterfat is regarded as and source as the relevant material with negative properties such as cholesterol and saturated fatty acid.Result as new scientific discovery, considered the effect of the cholesterol in the food now in more complicated mode, meanwhile, because the quite a large amount of cholesterol in the human body is that health itself produces, therefore the edible food that contains cholesterol of appropriateness it is believed that it is that reasonably this viewpoint is generally accepted.
With chain length is the relevant negative effect of saturated fatty acid of 12～16 C atoms, and particularly relevant with the generation of vascular diseases negative effect is incontrovertible.Therefore, think that still butterfat (as the source of these aliphatic acid) is more worthless fat.
Up to the present prior art is all not too paid attention to butterfat natural containing and is not had structure in the plant fat, and this structure have only by corresponding modification (ester exchange) pay a large amount of effort with oriented approach from the plant fat manufacturing: this is called as " structured lipid ".
" structured lipid " is meant following fat and grease, wherein, the structure that changes triglycerides with oriented approach makes that (these positions are called as sn-1, sn-2 and sn-3 to three fatty acid radicals that are connected in glycerol molecule according to its position, wherein sn-1 and sn-3 are basic identical because of all being positioned at the outside, and sn-2 refers to the center all the time) with oriented approach generation ester exchange, its mode is to make some aliphatic acid mainly be present in the sn-2 position.There is the whole bag of tricks can realize above-mentioned situation, and has corresponding product: for example from the BETAPOL of Dutch Loders Croklaan B.V.Wormerveer company.This product that is obtained by vegetable oil by enzymic transesterification is used for feeding infant by special exploitation, and verified, and the calcium that has obtained to increase in the baby absorbs and surpassed 30% result.This product is characterised in that, the palmitic acid (C-16) that 45% the sn1/sn3 position that mainly appears at plant fat usually arranged approximately is present in sn-2 position in this product as the result of ester exchange.
Antipodal therewith is that plant fat and grease constitute (Porsgaard, T. and Hoy, CE, J.Nutr.130:1619-1624 (2000) with the form that palmitic acid does not see favourable sn-2 position (and being mainly seen in the sn-1/sn-3 position); Weber, N, etc., J.Nutr.133:435-441 (2003)).
These mechanism (by mistake) cause calcium to be absorbed in being in very disadvantageous situation among the human nutriology: as the result of above-mentioned " shortcoming " of butterfat, great majority are paid close attention to healthy crowd food plant fat but not butterfat.Meanwhile, to build and keep bone in order to take measures and to add calcium (for example as the salt in the nutritional supplement); Yet in these cases, owing in alimentary canal, form calcium soap, thereby have only 60% calcium to be absorbed by human body.Under slightly better situation, the still edible dairy products that are rich in calcium of people, but preferred low fat milk goods.Therefore, so very disadvantageous combination appearring more and more: wherein, particularly pays close attention to crowd's food plant fat (palmitic acid is positioned at the sn-1/sn-3 position) in edible calcium of nutrition.This combination has stoped the edible calcium of suitable vast scale to be absorbed by human body.
Though the infant nutrition scholar has promptly known principle (Lucas, A. etc., the Arch.Dis.Child 77:F178-F184 (1997) that prevents to form calcium soap in alimentary canal for many years; Nelson, CM and InnisSM., Am.J.Clin.Nutr.70:62-69 (1999); Ostrom KM. etc., J, Am Coll.Nutr.21:564-569 (2002)), but found that this principle can't be applied in the daily human nutrition in practice.In fact, document description is arranged calcium stoped absorbing again of fat and caused the absorption of fat in the alimentary canal to reduce (Jacobsen, R. thus by in alimentary canal, forming calcium soap; Lorenzen, J.K; Toubro, S.; Krog-Mikkelsen, I.; Astrup, A.; Intern.J.Obesity 29:292-301 (2005)).
In addition, point out also in the document that if desire realizes that calcium absorbs preferably, calcium must always provide with dairy products.Up to the present, (from cow's milk, have more than is from human milk to butterfat! ) fact that can make sizable contribution to this both specifically studied in the prior art and described, and also do not enter in people's the practical nutrition.
Summary of the invention
Therefore, the objective of the invention is to develop the product that can be used for optimizing human calcium's absorption.
Theme of the present invention is to use the composition manufacturing that contains at least a butterfat to improve calcium absorption reagent.
The invention is characterized in, can absorb by using the calcium that said composition significantly improves human body.This means and to avoid additionally using.
Butterfat is made of the butterfat component such as physical separation such as butter, perhaps is made of the newborn component that is rich in butterfat such as the milk wet goods.The butterfat of preferably from cow's milk, separating.Alternatively, can be used according to the invention take the butterfat of other animal species such as goat, sheep and camel freely.In addition, can improve these butterfat components from nutrition: can carry out heredity to ox for this reason and select, feed and/or can carry out classification to butterfat and handle (by crystallization targetedly) in mode targetedly by corresponding measure.
Therefore, be included in (wet goods of for example suckling) in the newborn component or can be used for butterfat used in the present invention by (for example butter) butterfat that the Ruzhong obtains by physical partition method.
Butterfat is preferably the newborn component of physical separation.In addition, described butterfat does not carry out such as any chemical changes such as ester exchanges.
Can change butterfat in the following manner by corresponding natural measure: make fatty acid profile and/or distribution of fatty acids in the triglyceride structure on physiology, embody more valuable characteristic.This promptly contains less palmitic acid altogether and/or has palmitic acid in the sn-2 position in triglycerides situation.Can realize the change of these parameters by the kind (Huo Sitan kind, west, pool kind or the blue kind of Fu Lisi etc.) of selection ox.Yet it is more effective to use the plant that has contained desired fats acid to carry out the specific aim nursing, and this is because many nutritious described aliphatic acid are directly incorporated into the Ruzhong.There are extensive studies (Palmquist, D.L. etc., J.Dairy Sci.76:1753-1771 (1993) about this respect; DePeters E.J. etc., J.Dairy Sci.84:929-936 (2001); Bell, J.A. etc., J.Dairy Sci.89:733-748 (2006); Allred S.L. etc., J.Dairy Sci.89:234-248 (2006); Nielsen, T.S. etc., Reprod.Nutr.Dev.46:699-712 (2006)).In the practice, for example exist to use rape, soybean and hybridization sunflower to change the way of fatty acid profile in the following manner: reduces nutritionally more disadvantageous saturated fatty acid (C12～C16) with for example significantly increase CLA.To mainly be combined in the butterfat with the palmitic acid (C16) that low ratio (seeing absolute quantity) is present in the butterfat in the sn-2 position.Also there are some researchs (DePeters E.J. etc., J.Dairy Sci.84:929-936 (2001) on the one hand about this; Porsgaard, T. and Hoy, CE, J, Nutr.130:1619-1624 (2000)).
A kind of diverse technology is the butterfat classification (Lai, H-C. etc., J.Dairy Sci.78:794-803 (1995)) by the specific aim crystallization.This technology makes to make and it is characterized by the much lower liquid butterfat component of palmitic acid content.This component is nutritionally also more favourable to human body.
The above-mentioned change of butterfat means can avoid all shortcomings that butterfat exists on the widely used road in healthy food, and the advantage of " the structured lipid character " of breast can be used for improve sanatory product that calcium absorbs.
The butterfat of composition used in the present invention preferably contains the esterification palmitic acid of 10%～50% (with respect to the percentage by weight of butterfat).Preferably in triglycerides used in the present invention there are 18 weight %～35 weight %, are preferably the palmitic acid of 22 weight %～28 weight % especially.The described palmitic acid of 20 weight %～75 weight % is arranged in the sn-2 position of glycerine (the palmitic acid total amount that exists with respect to triglycerides).The palmitic acid of preferred 35 weight %～50 weight %, preferred especially 40 weight %～45 weight % is positioned at the sn-2 position.
This means that in alimentary canal the palmitic acid on the glycerine keeps esterification (sn-2) (in alimentary canal at first from sn-1/sn-3 position separation of fatty acids), thereby described palmitic acid is not discharged but absorb as monoglyceride.This be because, palmitic acid and calcium in alimentary canal, formed be called calcium soap be not material that human body absorbed, and cause in the food quite that the calcium of vast scale (above 30%) is not absorbed by human body.This principle of avoiding calcium soap to form has been imitated breast milk, is connected in sn-2 position and known this lipid structure up to 80% palmitic acid and has sizable contribution for the very excellent absorption from the calcium of breast milk in breast milk.
Yet, use and also can realize this principle from the breast of other animal.For example, in cow's milk, there is 35%～55% palmitic acid also to be contained in the sn-2 position similarly approximately.Regrettably, until today cow's milk this character all be almost scientific circles and ignore (comparing) with breast milk.Animal breast (the most important thing is cow's milk for European crowd) contains quite a large amount of calcium, these calcium are utilized by the young man as far as possible effectively, thereby the Nature has been successfully by having created the directed sn-2 position that imports butterfat of palmitic acid the structured lipid of natural generation, and described structured lipid helps the good absorption from the calcium in Ruzhong.
Also surprisingly find, with calcium only is provided, only provides calcium with lactoprotein or only provide calcium to compare as the situation of food source with fat, if also use lactoprotein (and/or its subfraction) simultaneously except butterfat, composition then of the present invention can cause calcium absorption (surpassing 20%) in the much better body.In addition, verified when butterfat is combined with lactoprotein, consumer's such product of can more taking like a shot.
The specific embodiment
Therefore, in a preferred embodiment, will contain
-at least a butterfat and
The composition of the present invention of-at least a lactoprotein and/or at least a milk protein hydrolyzates is used for manufacturing and improves calcium absorption material.
Obtain lactoprotein by the albumen that separates the Ruzhong.For example, can be with casein, PROVON 190 and/or lactalbumin as simple component as lactoprotein of the present invention.
For milk protein fractions, except the whey of the Caseinum componemt that separates and/or separation, also can use the subfraction of these lactoproteins or the corresponding product behind the proteolysis.
Casein as naturally occurring albumen is the part of lactoprotein, and lactoprotein has 20% to be made of lactalbumin and about 80% to be made of casein approximately.The calcium in Ruzhong mainly combines with casein.Casein can be in conjunction with a large amount of calcium.This means that calcium is evenly distributed in the liquid and can accumulate in the bottom with sedimentary form.Yet casein has the shortcoming that goes out at acid pH sinking precipitation, makes the calcium of casein combination not be suitable for acidic products.
Existing in recent years various scientific research group studies calcium combine with caseic, and in this process, found the principle of calcium binding peptides.It is found that caseic some part combines well especially with calcium, and these parts have and protein bound phosphate.Produce the CPP (CPP) that combines well especially with calcium during casein hydrolysis.From chemical terms, CPP is the one group of peptide that is derived from casein or casein fragment and contains at least one phosphate.Present calcium solution by using CPP to obtain to clarify very much.Can be purchased this CPP (for example, CPP DMV) at present.
PROVON 190 (GMP) discharges from casein by the effect of renin in cheese production, and is found in after cheese production in the component that is called whey component.From chemical terms, as κ-caseic hydrophilic segment, PROVON 190 is the κ-casein fragment that has 106～169 amino acid sequence.Therefore PROVON 190 is also referred to as casein PROVON 190 or CMP.PROVON 190 exists with 11 kinds of different genetic variants, and wherein A and B are modal genetic variants.PROVON 190 can also contain the sugar chain that glucosides connects.There is 30%～50% GMP to contain the sugar chain that glucosides connects usually approximately.PROVON 190 does not contain any aromatic amino acid, and also not containing can be through its phosphate in conjunction with calcium.
The casein in Ruzhong and calcium form stable structure (being called casein micelles).CPP (CPP) and PROVON 190 (GMP) can discharge from casein by hydrolytic process.
For example, CPP and/or the GMP component of No. 102005033630.2, patent application DE can be used for application of the present invention, herein by with reference to incorporating its full content into the application.For this reason, can in extensive studies, detect the utilizability and the calcium associativity of better calcium.In addition, testing the protein content that is suitable for various milk protein fractions most in the test widely.These find to have drawn thus preferred protein content and with the corresponding proportion of butterfat.Therefore, preferred following albumen (having provided adult's consumption every day of recommendation in every kind of situation): GMP (5g～10g) and/or CPP (2g～10g) and/or casein (20g～40g) and/or be rich in the lactalbumin (40g～60g) of GMP (sweet).
What is interesting is, select or in addition, find that also lactalbumin and hydrolysate thereof are suitable for combining with calcium as another kind.Yet described combination is so effective not as the connection of above-mentioned casein and hydrolysate thereof.But lactalbumin and hydrolysate thereof can be used for the calcium combination equally effectively with enough a large amount of ratios; Just need to use the amount bigger than casein.Yet for many products, the amount of albumen is more inessential, so casein (and/or its hydrolysate) or intend can selecting to use according to required should being used for the lactalbumin (and/or its hydrolysate) of relatively large use.
For example, can use the lactalbumin that is purchased and hydrolysate thereof as lactoprotein.Yet, in the case, need compare about 2～4 times amount with required casein usually and realize good calcium combination.In the case, not all lactalbumin and hydrolysate thereof are all suitable equally.Find in the practice that known material as acid constituents (its isoelectric point is lower than pH 6.0) is optimum.
In composition of the present invention, the weight ratio between butterfat and the lactoprotein should be 0.0625～5, is preferably 0.5～4, is preferably 1～3 especially.This depend in each case albumen and the type of instant food.
The amount ratio that is used for improving the composition butterfat of the present invention (where applicable also has lactoprotein) that calcium absorbs can be in following ranges, and described scope is by not knowing by modulating the common dairy products that each newborn component makes.Theme of the present invention realizes by the composition that is made of concoction that still described concoction is by the newborn component manufacturing that obtains by different physical methods.
Modulation breast be defined as by in skimmed milk powder, add entry and add separately the liquid breast that butterfat obtains its degree that reaches the required fat content of setting (referring to Handbuch der Milch-undMolkereitechnik[Handbook of milk and dairy technology], Verlag Th.MannGmbH; Co.KG, 45894 Gelsenkirchen, 2003,412 pages).Similarly, modulation dairy products (for example ice cream) are too by the composition manufacturing that separates in advance.
In preparation, provide the combination of butterfat, lactoprotein and calcium more favourable in principle together, thereby because can select the best relation between the component to guarantee that best calcium absorbs so the most reliably.But, also can provide calcium with the form of corresponding nutritional supplement.
Therefore in another preferred embodiment, composition of the present invention is taken with the calcium of following form, and described form is at least a salt of checking and approving through food and/or medical rules.In the case, whenever take 1000mg calcium (this is simultaneously corresponding to adult's consumption every day for recommending), should take about 60g～about 400g butterfat/milk protein composition of the present invention simultaneously.Whenever taking 1000mg calcium preferably takes about 80g～about 150g, especially preferably takes about 100g composition of the present invention.Described at least a calcium salt can be contained in the identical product, promptly in the same administration form of composition of the present invention, also can take near the time of taking butterfat of the present invention (where applicable also has lactoprotein) composition as far as possible.
In principle, the calcium source and every day consumption should keep a certain ratio with amount every day of butterfat/milk protein composition.The salt of all calcics of checking and approving through food and/or medical rules can be used as the calcium source.For being without loss of generality, mention some calcium salts in the mode of example below: calcium carbonate, calcium chloride, calcium citrate, calcium gluconae, calcium glycerophosphate, calcium lactate, tricalcium orthophosphate, calcium oxide and/or calcium hydroxide.
In embodiments of the present invention, it is contemplated that interpolation mineral matter and/or trace element in composition of the present invention.For being without loss of generality, possible mineral matter or trace element have been mentioned in the mode of example below: magnesium, copper, iron, selenium, fluorine, iodine, manganese.For the calcium deposition problems in the anti-hemostatic tube, for example can in composition of the present invention, also add magnesium.In the case, can add all magnesium salts of checking and approving through alimentary codex.Recommendation is that the magnesium of 250mg is as dosage every day (be suitable for adult) with maximum.
Also preferably in compositions for use of the present invention, add vitamin, especially preferably add vitamin D, the again absorption of vitamin D collaborative promotion calcium in small intestine.Operable other supported one's family and have for example B family vitamin (B1, B6, B12), vitamin E, A or K.
In the preferred implementation of described composition, added such as Soluble Fibers such as FOS, galactooligosaccharide and/or phytosterols in application of the present invention.
For stablizing composition of the present invention, can use such as conventional emulsifiers such as lecithin, monoglyceride, diglycerides or through checking and approving the emulsifying agent that is used for food manufacturing.
Composition of the present invention both can be used as the additive in the food, also can be used as nutritional supplement or pharmaceutical preparation.
In principle, composition of the present invention can be used for making the reagent of liquid state, solid-state, powdery, bulk or any other state of aggregation.The state of aggregation decision administration form of product.Preferred oral is used.Yet, also can carry out (directly entering stomach), nasal feeding (entering stomach by nose) in the stomach, stomach and intestine outer (getting around gastronintestinal system directly enters in the body) or intravenous (directly entering vein) and use via probe.
Can make then as the product of bread and cheese or the product in the nutraceutical field.Yet, also can make the product that ranges medicine or self-medication field.
Can use composition of the present invention in many ways.Be without loss of generality its suitable especially milk product (comprising baby food), yogurt preparation, candy, powder, tablet, bulk form, rod, gel or emulsion as form of emulsion.
Typical application is to be used in dairy products, baby food, yoghourt (quark) and yogurt food, whey beverage, dessert, ice cream, fruit rod, tablet, capsule, spray or the unit-dose powder bag.
By reference the full content of described all applications of context, patent and communique is incorporated among the application.
Can think that even other embodiment is not provided, those skilled in the art also can be applied to foregoing description its maximum magnitude.Therefore, should think that described preferred implementation and embodiment are descriptive, and can never limit the scope of the invention.
Embodiment
Embodiment 1
The composition that provides for application of the present invention can contain composition as shown in table 1 below (adult's dosage every day of recommendation provides as an example).
Table 1: may the forming of the composition that provides for application of the present invention
Individual components Weight ratio Example (daily dose *)
Butterfat component :-butter fat About 1 ?40.0g
Milk protein fractions :-lactalbumin-CPP-PROVON 190 About 1 about 0.06 about 0.12 ?40.0g ?2.5g ?5.0g
*) this daily dose should together take with 1000mg calcium.
Embodiment 2
Be fabricated to application of the present invention and the adult that provides uses beverage by following composition:
208.5g skimmed milk
81g sweet whey powder
37g cream
3.45g?CPP
This product contains enough calcium because of its raw material, thereby need not to add calcium compound again.
Dose is every part of 330ml, and should not surpass 800ml every day.
Embodiment 3
Be fabricated to application of the present invention and the infant formula (providing each composition) that provides by following composition according to the final infant formula of 100ml:
70.5 water (demineralizing)
The 21g skimmed milk
5.2g whey powder (demineralizing)
1.8g vegetable oil
2.5g lactose
1.7g butter
170mg GMP (PROVON 190)
90mg CPP (CPP)
Other composition: emulsifying agent, minerals and vitamins, these compositions must meet at the legal provision of Europe of infant formula instruction with about the German regulations of nutraceutical
Figure G2008800155611D00101
Dose depends on infant age, and is about 1 liter/day.

Claims (14)

1. contain the application of the composition of at least a butterfat, described composition is used for manufacturing and improves calcium absorption reagent.
2. the application of composition as claimed in claim 1 is characterized in that, described butterfat is the newborn component without the physical separation of chemical modification.
3. the application of composition as claimed in claim 1 or 2 is characterized in that, described butterfat contains the esterification palmitic acid of 10 weight %～50 weight %, preferred 18 weight %～35 weight %, preferred especially 22 weight %～28 weight %.
4. the application of composition as claimed in claim 3 is characterized in that, makes the described palmitic acid of 20 weight %～75 weight %, preferred 35 weight %～50 weight %, preferred especially 40 weight %～45 weight % bit esterified at the sn-2 of glycerine.
5. as the application of each described composition in the claim 1～4, described composition comprises
-at least a butterfat and
-at least a lactoprotein and/or at least a milk protein hydrolyzates.
6. the application of composition as claimed in claim 5 is characterized in that, described lactoprotein is the newborn component of physical separation.
7. as the application of claim 5 or 6 described compositions, it is characterized in that the weight ratio of described butterfat and described lactoprotein is 0.0625～5, be preferably 0.5～4, more preferably 1～3.
8. as the application of each described composition in the claim 1～7, it is characterized in that described composition is used in combination with at least a salt of checking and approving through food and/or medical rules, wherein the composition of 60g～400g is used with the calcium of 1000mg.
9. as the application of each described composition in the claim 1～8, it is characterized in that at least a calcium salt is selected from the group of being made up of calcium carbonate, calcium chloride, calcium citrate, calcium gluconae, calcium glycerophosphate, calcium lactate, tricalcium orthophosphate, calcium oxide and calcium hydroxide.
10. as the application of each described composition in the claim 1～9, it is characterized in that, wherein added mineral matter, trace element and/or vitamin and emulsifying agent.
11. the application as each described composition in the claim 1～10 is characterized in that, has wherein added Soluble Fiber.
12. the application of composition as claimed in claim 11 is characterized in that, has wherein added FOS, galactooligosaccharide and/or phytosterol.
13. the application as each described composition in the claim 1～12 is characterized in that, has wherein added emulsifying agent.
14. as the application of each described composition in the claim 1～13, described composition is used as the additive in food, nutritional supplement or the pharmaceutical preparation.
CN200880015561A 2007-05-11 2008-05-07 Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs Pending CN101686726A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610173158.8A CN105962374A (en) 2007-05-11 2008-05-07 Composition application

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007022694.4 2007-05-11
DE102007022694A DE102007022694A1 (en) 2007-05-11 2007-05-11 Milk fat milk protein composition to improve calcium absorption
PCT/EP2008/055597 WO2008138821A1 (en) 2007-05-11 2008-05-07 Milk fat-milk protein composition (preferably esterified with palmitic acid) for improving calcium absorption

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610173158.8A Division CN105962374A (en) 2007-05-11 2008-05-07 Composition application

Publications (1)

Publication Number Publication Date
CN101686726A true CN101686726A (en) 2010-03-31

Family

ID=39645456

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880015561A Pending CN101686726A (en) 2007-05-11 2008-05-07 Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs
CN201610173158.8A Pending CN105962374A (en) 2007-05-11 2008-05-07 Composition application

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610173158.8A Pending CN105962374A (en) 2007-05-11 2008-05-07 Composition application

Country Status (6)

Country Link
EP (1) EP2152101A1 (en)
CN (2) CN101686726A (en)
DE (1) DE102007022694A1 (en)
RU (1) RU2468610C2 (en)
UA (1) UA99614C2 (en)
WO (1) WO2008138821A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106262925A (en) * 2011-06-16 2017-01-04 N·V·努特里奇亚 The metabolism trace effect of custom-designed lipid composition
CN107105738A (en) * 2014-12-19 2017-08-29 雀巢产品技术援助有限公司 Infant nutrition containing aminosal, ionized calcium and palmitic acid
CN107105739A (en) * 2014-12-19 2017-08-29 雀巢产品技术援助有限公司 Infant nutrition containing aminosal and palmitic acid

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1399244B1 (en) * 2009-07-31 2013-04-11 Pharmarte S R L FORMULATION OF BARRIER SPECIFIC FOR PREGNANCY.
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
DE102019205767A1 (en) * 2019-04-23 2020-10-29 Beiersdorf Ag Deodorant or antiperspirant composition
AU2021395877A1 (en) 2020-12-11 2023-06-08 Frieslandcampina Nederland B.V. Fat blend suitable for infant nutrition
WO2023232962A1 (en) 2022-06-02 2023-12-07 Frieslandcampina Nederland B.V. Fat blend suitable for infant nutrition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2890379B2 (en) * 1990-08-28 1999-05-10 雪印乳業株式会社 Calcium absorption promoting nutrient, food and feed
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
NL9401958A (en) * 1994-11-23 1996-07-01 Friesland Brands Bv Milk product enriched with eggshell flour.
EP1062876A1 (en) * 1999-02-25 2000-12-27 Societe Des Produits Nestle S.A. Caseinoglycomacropeptides as calcification agent
US6620427B2 (en) * 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
IL158555A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Human breast milk lipid mimetic as dietary supplement
KR101368603B1 (en) * 2005-04-27 2014-02-27 엔지모테크 리미티드 Human Milk Fat Substitutes
DE102005033630A1 (en) 2005-07-19 2007-01-25 Humana Gmbh Calcium-peptide component

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106262925A (en) * 2011-06-16 2017-01-04 N·V·努特里奇亚 The metabolism trace effect of custom-designed lipid composition
CN107105738A (en) * 2014-12-19 2017-08-29 雀巢产品技术援助有限公司 Infant nutrition containing aminosal, ionized calcium and palmitic acid
CN107105739A (en) * 2014-12-19 2017-08-29 雀巢产品技术援助有限公司 Infant nutrition containing aminosal and palmitic acid

Also Published As

Publication number Publication date
CN105962374A (en) 2016-09-28
DE102007022694A1 (en) 2008-11-13
UA99614C2 (en) 2012-09-10
RU2468610C2 (en) 2012-12-10
WO2008138821A1 (en) 2008-11-20
EP2152101A1 (en) 2010-02-17
RU2009144036A (en) 2011-06-20

Similar Documents

Publication Publication Date Title
CN101686726A (en) Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs
Park et al. Physico-chemical characteristics of goat and sheep milk
O’Mahony et al. Milk: an overview
Barłowska et al. Nutritional value and technological suitability of milk from various animal species used for dairy production
ES2478869T3 (en) Liquid enteral nutritional composition suitable for tube feeding
CN101636167B (en) Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same
ES2764089T3 (en) Nutritional composition that has lipophilic compounds with improved solubility and bioavailability
US20110223282A1 (en) Nutritional composition with anti-regurgitation properties
WO2019104390A1 (en) Milk substitute compositions
CN105188411A (en) Method of enhancing bioavailability of DHA and other lipid-soluble nutrients
CN105188409A (en) Infant nutritional product with RRR alpha-tocopherol
CN112998080A (en) Infant formula milk powder added with yolk phospholipid, soybean phospholipid and milk phospholipid
ES2208256T5 (en) COW MILK AND FEEDING PRODUCT OF A COW TO OBTAIN SUCH MILK.
WO2015187795A1 (en) Nutritional compositions comprising a lipophilic active ingredient
JP6449648B2 (en) Nutritional composition
WO2007140589A1 (en) Dairy product
CN108157512A (en) A kind of formula milk for strengthening 6 ~ 12 months infant's gastrointestinal functions
Park Impact of goat milk and milk products on human nutrition.
Wells Nutritional considerations in infant formula design
RU2311039C2 (en) Product for enteral feeding
de la Fuente et al. Sheep milk
Sharma et al. Role of omega-3 fatty acids, conjugated linoleic acid and phytosterols in improving functionality of dairy products
JP2006022068A (en) Serum lipid metabolism ameliorative agent
US20170367395A1 (en) Infant nutrition with hydrolysed protein and palmitic acid
RU2311038C2 (en) Product for enteral feeding

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100331